Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
about
shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapyPromising oncolytic agents for metastatic breast cancer treatmentAnti-tumor activity of a miR-199-dependent oncolytic adenovirusCalcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism.A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.Gene therapy of gynaecological diseases.Cancer, stem cells, and oncolytic viruses.Serotype chimeric human adenoviruses for cancer gene therapy.CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.Novel oncolytic viral therapies in patients with thoracic malignancies.Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
P2860
Q26765364-CD114411-5D7E-4DD2-B0D6-BC2DAA89B2C5Q26830620-DD0D1FFC-011F-446D-86E0-C83E2A18F1D1Q27307206-8ADAC2F7-E9C4-41F0-BB03-173CD355C3CDQ33711997-9FE6C5F7-F4CC-4150-B2B2-72F830105D8FQ34183436-843E3E80-F9F2-44C3-9856-B649001157D1Q34667746-5E1C32FB-C030-4629-A5C7-0071DA1918BCQ35101968-9ABE7905-DD00-482F-AD0C-D62CB85A6707Q36220624-9B6A1EA8-5E13-4EE5-81FC-52E9636EDC41Q36710972-8BAEFA31-A573-4EB0-88DF-3F29B9722B8AQ36922247-C32759C1-0E57-43EE-9B1A-73E5E42241DBQ37209758-970401AB-3EAE-4C1A-A4F8-3903E90EB787Q37945193-5714F033-4895-4411-9F69-B5DF23EB4F15Q39048893-BDA55949-F312-4E98-8D41-0D24C5F370C1Q39067827-4D634627-D05F-49DB-AEA3-813502E40115Q39491840-1036AB6A-3825-4784-902D-065A118D119FQ39532576-3D75EEE4-144C-45E4-8A23-50D3013AF903Q39851910-55218C5B-FE1C-40FC-B83A-FA6D9BD4CE67Q45876668-2E4C72E7-A489-4EC2-97A4-3C55DF411F20
P2860
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Systemic efficacy of oncolytic ...... tory metastatic breast cancer.
@en
type
label
Systemic efficacy of oncolytic ...... tory metastatic breast cancer.
@en
prefLabel
Systemic efficacy of oncolytic ...... tory metastatic breast cancer.
@en
P2093
P50
P356
P1476
Systemic efficacy of oncolytic ...... tory metastatic breast cancer.
@en
P2093
Karl von Smitten
Merja Särkioja
Tuuli Ranki
P2860
P304
P356
10.1002/IJC.22627
P577
2007-07-01T00:00:00Z